Quarter Ended

Six Months Ended

December 31,

2021

2020

2021

2020

Earnings per share – basic:

Net earnings, including noncontrolling interest

$

72,059

$

46,144

$

141,040

$

79,538

Less net earnings (loss) attributable to noncontrolling interest

(8,114

)

(130

)

(8,748

)

(130

)

Net earnings attributable to Bio-Techne

$

80,173

$

46,274

$

149,788

$

79,668

Income allocated to participating securities

(34

)

(37

)

(70

)

(50

)

Income available to common shareholders

$

80,139

$

46,237

$

149,718

$

79,618

Weighted-average shares outstanding – basic

39,310

38,691

39,202

38,614

Earnings per share – basic

$

2.04

$

1.20

$

3.82

$

2.06

Earnings per share – diluted:

Net earnings, including noncontrolling interest

$

72,059

$

46,144

$

141,040

$

79,538

Less net earnings (loss) attributable to noncontrolling interest

(8,114

)

(130

)

(8,748

)

(130

)

Net earnings attributable to Bio-Techne

$

80,173

$

46,274

$

149,788

$

79,668

Income allocated to participating securities

(34

)

(37

)

(70

)

(50

)

Income available to common shareholders

$

80,139

$

46,237

$

149,718

$

79,618

Weighted-average shares outstanding – basic

39,310

38,691

39,202

38,614

Dilutive effect of stock options and restricted stock units

1,897

1,566

1,957

1,521

Weighted-average common shares outstanding – diluted

41,207

40,257

41,159

40,135

Earnings per share – diluted

$

1.94

$

1.15

$

3.64

$

1.98